Novartis’ proposed drug for adults diagnosed with a certain type of advanced prostate cancer was given the green light for commercialization.
Amgen is snapping up privately held Teneobio and the company’s class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.
Numerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
The U.S. Food and Drug Administration approved FoundationOne Liquid CDx, a new pan-tumor liquid biopsy test that is indicated for use as a companion diagnostic for four FDA-approved precision therapies.
Roche reported mixed results for a late-stage trial of an experimental drug for prostate cancer, the Swiss drugmaker said on Friday, missing the goal in the overall population but cutting risk of disease worsening in patients with mutated tumors.
The U.S. Food and Drug Administration approved Clovis Oncology Inc.’s drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.
Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here is a look at what is on the schedule for the next two weeks.
A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.
Dendreon Pharmaceuticals released results of a first-of-its-kind study examining survival outcomes in men with metastatic castrate-resistant prostate cancer who were treated with PROVENGE (sipuleucel-T) and oral agents in a real-world treatment setting.
AstraZeneca’s cancer drug Lynparza was successful in helping patients with metastatic prostate cancer and certain genetic mutations live longer without the disease worsening compared with the standard of care.
